Co-Author
This page shows the publications co-authored by E. Orav and Howard Weiner.
Connection Strength
0.972
-
Double-blind study of true vs. sham plasmapheresis in patients being treated with immunosuppression for acute attacks of multiple sclerosis. Prog Clin Biol Res. 1990; 337:283.
Score: 0.106
-
Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology. 1989 Sep; 39(9):1143-9.
Score: 0.104
-
A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler. 2005 Oct; 11(5):573-82.
Score: 0.079
-
Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: a longitudinal study. Arch Neurol. 2001 Jan; 58(1):115-21.
Score: 0.057
-
Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch Neurol. 2000 Aug; 57(8):1183-9.
Score: 0.055
-
Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. J Neuroimmunol. 2000 May 01; 104(2):164-73.
Score: 0.054
-
Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler. 1999 Dec; 5(6):403-9.
Score: 0.053
-
Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler. 1999 Oct; 5(5):349-54.
Score: 0.052
-
Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis. Neurology. 1999 Sep 11; 53(4):758-64.
Score: 0.052
-
Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol. 1997 Aug; 54(8):1018-25.
Score: 0.045
-
Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of a phase III pivotal trial. Ann N Y Acad Sci. 1996 Feb 13; 778:243-50.
Score: 0.041
-
Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology. 1995 Feb; 45(2):251-5.
Score: 0.038
-
Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology. 1994 Nov; 44(11):2120-4.
Score: 0.037
-
Effects of oral administration of type II collagen on rheumatoid arthritis. Science. 1993 Sep 24; 261(5129):1727-30.
Score: 0.034
-
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology. 1993 May; 43(5):910-8.
Score: 0.034
-
Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 1993 Feb 26; 259(5099):1321-4.
Score: 0.033
-
Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis. J Neuroimmunol. 1991 May; 32(2):149-58.
Score: 0.029
-
Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology. 1988 Jul; 38(7 Suppl 2):9-14.
Score: 0.024
-
Cumulative experience with high-dose intravenous cyclophosphamide and ACTH therapy in chronic progressive multiple sclerosis. Ann N Y Acad Sci. 1988; 540:535-6.
Score: 0.023
-
Kinin B1 receptor expression on multiple sclerosis mononuclear cells: correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability. Arch Neurol. 2005 May; 62(5):795-800.
Score: 0.019
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.